PI3K: from the bench to the clinic and back
- PMID: 20549473
- PMCID: PMC2954281
- DOI: 10.1007/82_2010_65
PI3K: from the bench to the clinic and back
Abstract
From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here, we give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here.PI3K has become a very intense area of research, with over 2,000 publications on PI3K in PubMed for 2009 alone. The expectations for a therapeutic impact of intervention with PI3K activity are high, and progress in the clinical arena is being monitored by many. However, targeted therapies almost invariably encounter roadblocks, often exposing unresolved questions in the basic understanding of the target. PI3K will most likely be no exception. Below, we describe some of these early "surprises" and how these inform and shape basic science investigations.
Similar articles
-
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.Semin Cancer Biol. 2019 Dec;59:125-132. doi: 10.1016/j.semcancer.2019.07.009. Epub 2019 Jul 16. Semin Cancer Biol. 2019. PMID: 31323288 Review.
-
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.Mol Cancer Ther. 2011 Dec;10(12):2426-36. doi: 10.1158/1535-7163.MCT-11-0446. Epub 2011 Oct 13. Mol Cancer Ther. 2011. PMID: 21998291
-
Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.Cancer Treat Rev. 2014 Sep;40(8):980-9. doi: 10.1016/j.ctrv.2014.06.006. Epub 2014 Jul 3. Cancer Treat Rev. 2014. PMID: 25037117 Review.
-
Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases.Prog Med Chem. 2009;48:81-131. doi: 10.1016/s0079-6468(09)04803-6. Prog Med Chem. 2009. PMID: 21544958 Review. No abstract available.
-
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.Cancer Chemother Pharmacol. 2013 Apr;71(4):829-42. doi: 10.1007/s00280-012-2043-3. Epub 2013 Feb 3. Cancer Chemother Pharmacol. 2013. PMID: 23377372 Review.
Cited by
-
Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery.Pharmaceutics. 2022 Jan 27;14(2):302. doi: 10.3390/pharmaceutics14020302. Pharmaceutics. 2022. PMID: 35214039 Free PMC article. Review.
-
Expression of the RAE-1 family of stimulatory NK-cell ligands requires activation of the PI3K pathway during viral infection and transformation.PLoS Pathog. 2011 Sep;7(9):e1002265. doi: 10.1371/journal.ppat.1002265. Epub 2011 Sep 22. PLoS Pathog. 2011. PMID: 21966273 Free PMC article.
-
Disrupted neuronal trafficking in amyotrophic lateral sclerosis.Acta Neuropathol. 2019 Jun;137(6):859-877. doi: 10.1007/s00401-019-01964-7. Epub 2019 Feb 5. Acta Neuropathol. 2019. PMID: 30721407 Free PMC article. Review.
-
Role of cancer stem cells in the development of giant cell tumor of bone.Cancer Cell Int. 2020 Apr 25;20:135. doi: 10.1186/s12935-020-01218-7. eCollection 2020. Cancer Cell Int. 2020. PMID: 32351329 Free PMC article. Review.
-
Salvianolic acid B suppresses EMT and apoptosis to lessen drug resistance through AKT/mTOR in gastric cancer cells.Cytotechnology. 2021 Feb;73(1):49-61. doi: 10.1007/s10616-020-00441-4. Epub 2020 Nov 17. Cytotechnology. 2021. PMID: 33505113 Free PMC article.
References
-
- Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, Norman DG, Gaffney P, Reese CB, MacDougall CN, Harbison D, Ashworth A, Bownes M. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol. 1997a;7:776–89. - PubMed
-
- Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997b;7:261–9. - PubMed
-
- Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, Cron P, Cohen P, Lucocq JM, Hemmings BA. Role of translocation in the activation and function of protein kinase B. J Biol Chem. 1997;272:31515–24. - PubMed
-
- Arcaro A, Volinia S, Zvelebil MJ, Stein R, Watton SJ, Layton MJ, Gout I, Ahmadi K, Downward J, Waterfield MD. Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity. J Biol Chem. 1998;273:33082–90. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA115521-03/CA/NCI NIH HHS/United States
- BB/C505659/1/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- R01 CA078230-11/CA/NCI NIH HHS/United States
- BB/C505659/2/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- R01 CA107094-01A1/CA/NCI NIH HHS/United States
- R01 CA115521-04/CA/NCI NIH HHS/United States
- R01 CA107094-04/CA/NCI NIH HHS/United States
- CRUK_/Cancer Research UK/United Kingdom
- R01 CA115521-02/CA/NCI NIH HHS/United States
- R01 CA078230-10/CA/NCI NIH HHS/United States
- R01 CA115521/CA/NCI NIH HHS/United States
- R01 CA107094-05/CA/NCI NIH HHS/United States
- R01 CA107094/CA/NCI NIH HHS/United States
- R01 CA078230/CA/NCI NIH HHS/United States
- R01 CA107094-02/CA/NCI NIH HHS/United States
- P01 CA078045-10/CA/NCI NIH HHS/United States
- P01 CA078045-07/CA/NCI NIH HHS/United States
- R01 CA115521-01/CA/NCI NIH HHS/United States
- R01 CA078230-07/CA/NCI NIH HHS/United States
- MRC_/Medical Research Council/United Kingdom
- P01 CA078045-08/CA/NCI NIH HHS/United States
- R01 CA078230-08/CA/NCI NIH HHS/United States
- P01 CA078045/CA/NCI NIH HHS/United States
- R01 CA107094-03/CA/NCI NIH HHS/United States
- R01 CA078230-12/CA/NCI NIH HHS/United States
- P01 CA078045-06A1/CA/NCI NIH HHS/United States
- R01 CA078230-09/CA/NCI NIH HHS/United States
- P01 CA078045-09/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources